Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flutiform in COPD (The Effect study)
NCT01946620Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Oct 2013
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Mundipharma. Primary endpoint: Annual rate of moderate and severe COPD exacerbations at 52 weeks. Started Oct 2013; status: completed.
02
Drugs
fluticasone propionate + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01946620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946620.